BeOne Medicines Ltd. (ONC)
350.57
-3.90
(-1.10%)
USD |
NASDAQ |
Oct 12, 16:00
350.57
0.00 (0.00%)
After-Hours: 20:00
BeOne Medicines Free Cash Flow (Quarterly) : 436.10M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 436.10M |
| March 31, 2026 | 161.03M |
| December 31, 2025 | 381.19M |
| September 30, 2025 | 355.08M |
| June 30, 2025 | 200.23M |
| March 31, 2025 | -12.32M |
| December 31, 2024 | -17.32M |
| September 30, 2024 | 54.71M |
| June 30, 2024 | -205.54M |
| March 31, 2024 | -469.82M |
| December 31, 2023 | -388.55M |
| September 30, 2023 | -245.44M |
| June 30, 2023 | -415.36M |
| March 31, 2023 | -689.36M |
| December 31, 2022 | -439.55M |
| September 30, 2022 | -670.56M |
| June 30, 2022 | -428.93M |
| March 31, 2022 | -282.08M |
| December 31, 2021 | -666.14M |
| September 30, 2021 | -564.97M |
| June 30, 2021 | -458.80M |
| March 31, 2021 | 82.71M |
| Date | Value |
|---|---|
| December 31, 2020 | -367.02M |
| September 30, 2020 | -374.92M |
| June 30, 2020 | -295.55M |
| March 31, 2020 | -363.48M |
| December 31, 2019 | -282.64M |
| September 30, 2019 | -295.88M |
| June 30, 2019 | -67.55M |
| March 31, 2019 | -193.80M |
| December 31, 2018 | -209.53M |
| September 30, 2018 | -167.07M |
| June 30, 2018 | -127.75M |
| March 31, 2018 | -114.20M |
| December 31, 2017 | 74.82M |
| September 30, 2017 | -11.96M |
| June 30, 2017 | -67.82M |
| March 31, 2017 | -40.78M |
| December 31, 2016 | -34.20M |
| September 30, 2016 | -30.96M |
| June 30, 2016 | -24.71M |
| March 31, 2016 | -23.14M |
| December 31, 2015 | -20.18M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -84.15M |
| Idorsia Ltd. | -46.53M |